Inari Medical (NARI) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NARI shares.
View NARI analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1 year price targets for Inari Medical's stock. Their NARI share price forecasts range from $70.00 to $105.00. On average, they anticipate the company's share price to reach $89.11 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price.
View analysts price targets for NARI or view top-rated stocks among Wall Street analysts.

Inari Medical's stock was trading at $63.56 on January 1st, 2023. Since then, NARI shares have decreased by 4.6% and is now trading at $60.66.
View the best growth stocks for 2023 here.

Inari Medical saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,370,000 shares, an increase of 25.7% from the April 30th total of 2,680,000 shares. Based on an average daily volume of 838,900 shares, the short-interest ratio is currently 4.0 days. Approximately 7.0% of the shares of the company are sold short.
View Inari Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NARI earnings forecast.

Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, May, 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.19. The company had revenue of $116.17 million for the quarter, compared to analyst estimates of $110.30 million. Inari Medical had a negative trailing twelve-month return on equity of 6.78% and a negative net margin of 6.87%. Inari Medical's revenue was up 33.9% on a year-over-year basis. During the same period last year, the business earned ($0.06) earnings per share.

ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Principal Healthcare Innovators ETF (BTEC), Renaissance IPO ETF (IPO), Goldman Sachs Future Health Care Equity ETF (GDOC) and IQ Healthy Hearts ETF (HART).

Inari Medical updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $478.00 million-$488.00 million, compared to the consensus revenue estimate of $476.10 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

(NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Inari Medical trades on the NASDAQ under the ticker symbol "NARI."

Inari Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.89%), Wellington Management Group LLP (8.87%), Franklin Resources Inc. (4.89%), Price T Rowe Associates Inc. MD (3.26%), State Street Corp (2.90%) and Brown Advisory Inc. (2.29%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Mitch C Hill, Presidio Management Group X Ll, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends.

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NARI stock can currently be purchased for approximately $60.66.

Inari Medical (NASDAQ:NARI) has a market capitalization of $3.47 billion and generates $383.47 million in revenue each year. The company earns $-29,270,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

The company employs 1,100 workers across the globe.

Inari Medical's mailing address is 9 Parker Suite 100, Irvine CA, 92618. The official website for the company is www.inarimedical.com. The company can be reached via phone at 877-923-4747 or via email at ir@inarimedical.com.